Yvonne Y. Lau

发表

PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT RIFAMPICIN SINGLE DOSES: RELEVANCE OF FIRST-PASS EFFECT FROM HEPATIC UPTAKE TRANSPORTERS, AND INTESTINAL AND HEPATIC METABOLISM

Leslie Z. Benet, L. Benet, Yong Huang, 2006, Drug Metabolism and Disposition.

Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter Interplay

Leslie Z. Benet, Chi-Yuan Wu, L. Benet, 2004, Journal of Pharmacology and Experimental Therapeutics.

Pharmacokinetic and Pharmacodynamic Modeling of a Monoclonal Antibody Antagonist of Glucagon Receptor in Male ob/ob Mice

L. Gibiansky, M. Véniant, Peiming Ma, 2009, The AAPS Journal.

Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes

T. Boone, J. Xu, N. Chinookoswong, 2012, PloS one.

association with liver and adipose tissue effects -- of FGF21 in insulin-resistant mouse models Acute glucose-lowering and insulin-sensitizing action

F. Villarroya, F. Gonzalez, C. Billington, 2011 .

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.

N. Chinookoswong, Shu-Chen Lu, R. Lindberg, 2009, American journal of physiology. Endocrinology and metabolism.

ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Jeffrey W. Scott, Keunchil Park, Dong-Wan Kim, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Fully Human Monoclonal Antibodies Antagonizing the Glucagon Receptor Improve Glucose Homeostasis in Mice and Monkeys

Katherine A. Winters, C. Zhang, Y. Lau, 2009, Journal of Pharmacology and Experimental Therapeutics.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

J. Engelman, Michael Thomas, A. Shaw, 2014, The New England journal of medicine.

Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects

Jeffrey W. Scott, Y. Lau, D. Song, 2016, Journal of clinical pharmacology.

Application of time-dependent modeling for the exposure–efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients

Xinrui Zhang, P. Urban, Yvonne Y. Lau, 2019, Cancer Chemotherapy and Pharmacology.

Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems

Leslie Z Benet, L. Benet, Yong Huang, 2006, Journal of Pharmacology and Experimental Therapeutics.

Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC.

A. Shaw, E. Felip, F. D. De Braud, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.

Ying Cheng, C. Bai, Yi-long Wu, 2020, Lung cancer.

Liquid chromatography tandem mass spectrometry method for the quantitative analysis of ceritinib in human plasma and its application to pharmacokinetic studies

O. Heudi, F. Picard, O. Kretz, 2014, Analytical and Bioanalytical Chemistry.

P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC: Topic: Miscellaneous

Keunchil Park, R. Dziadziuszko, Dong-Wan Kim, 2017 .

A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST).

M. Heinrich, S. George, B. V. Van Tine, 2022, Journal of Clinical Oncology.

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

P. Postmus, Keunchil Park, R. Dziadziuszko, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mechanistic Modeling of Antigen Sink Effect for Mavrilimumab Following Intravenous Administration in Patients With Rheumatoid Arthritis

F. Magrini, Y. Lau, B. Wang, 2012, Journal of clinical pharmacology.

Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

V. Passos, Yvonne Y. Lau, Ying Hong, 2017, Journal of clinical pharmacology.

Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer

M. Shi, Yvonne Y. Lau, W. Gu, 2017, Cancer Chemotherapy and Pharmacology.

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors

F. D. De Braud, F. K. Hurtado, Ding Wang, 2021, Cancer Chemotherapy and Pharmacology.

Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects

D. Song, Yvonne Y. Lau, W. Gu, 2016, Journal of clinical pharmacology.